American Society of Hematology

Fig. 1.

$Fig. 1. In contrast to rapa, MP, FTY720, or MMF, CyA and FK inhibit development of long-term chimerism after BMT with cobl. / Results from 2 separate experiments are shown. All B6 mice (n = 5 or 6 per group) received 3 Gy TBI (day −1), 15 to 20 × 106Balb/c BMCs (day 0), anti-CD154 mAb (day 0), and CTLA4Ig (day 2). The percentages of donor-derived CD4+ cells (⋄), CD8+ cells (▪), B cells (▴), and monocytes/granulocytes (■) were evaluated by FCM. The fractions on each panel indicate the fraction of analyzed mice showing chimerism at the time point below. Standard-protocol groups (A, n = 5; B, n = 6) did not receive any additional treatment. Other groups received additionally CyA (C), FK (D), rapa (E), MP (F), FTY720 (G), or MMF (H). Each immunosuppressive drug was given for the first 4 weeks after BMT.$

In contrast to rapa, MP, FTY720, or MMF, CyA and FK inhibit development of long-term chimerism after BMT with cobl.

Results from 2 separate experiments are shown. All B6 mice (n = 5 or 6 per group) received 3 Gy TBI (day −1), 15 to 20 × 10⁶Balb/c BMCs (day 0), anti-CD154 mAb (day 0), and CTLA4Ig (day 2). The percentages of donor-derived CD4⁺ cells (⋄), CD8⁺ cells (▪), B cells (▴), and monocytes/granulocytes (■) were evaluated by FCM. The fractions on each panel indicate the fraction of analyzed mice showing chimerism at the time point below. Standard-protocol groups (A, n = 5; B, n = 6) did not receive any additional treatment. Other groups received additionally CyA (C), FK (D), rapa (E), MP (F), FTY720 (G), or MMF (H). Each immunosuppressive drug was given for the first 4 weeks after BMT.

This Feature Is Available To Subscribers Only